Synopsis
Researchers from the Institute of Nano Science and Technology in Mohali have introduced a new targeted nano-formulation for a safer treatment of Parkinson's disease, focusing on sustained hormone release and neuroprotection.Key Takeaways
- New targeted nano-formulation for Parkinson’s treatment.
- Facilitates sustained release of 17beta-oestradiol.
- Inhibits calpain to protect neurons.
- Restores BMI1 expression, enhancing mitochondrial health.
- Addresses oxidative stress in patients.
New Delhi, Jan 27 (NationPress) Researchers from the Institute of Nano Science and Technology (INST) in Mohali, which operates as an autonomous body under the Department of Science and Technology, revealed on Monday a pioneering targeted nano-formulation designed to provide a safer treatment option for individuals grappling with Parkinson’s disease.
This innovative nano-formulation facilitates the sustained release of a key hormone known as 17beta-oestradiol, essential for effective management of Parkinson’s. Numerous neurodegenerative and psychiatric disorders, including Parkinson's, stem from a disruption in the levels of 17 beta-oestradiol (E2) in the brain.
Despite the therapeutic promise of E2 in treating Parkinson’s, its peripheral side effects and the limited understanding of its molecular mechanisms have complicated its neurotherapeutic application, according to the research team. The findings, published in the journal Carbohydrate Polymers, detail how using Dopamine Receptor D3 (DRD3) conjugated to 17beta-oestradiol-loaded chitosan nanoparticles resulted in a sustained delivery of E2 to the brain.
“The targeted nano-formulation significantly inhibited the mitochondrial translocation of calpain, thus shielding neurons from damage induced by rotenone,” the researchers stated.
Additionally, in a rodent model, the targeted nano-delivery system successfully mitigated behavioral impairments. The study also unveiled for the first time that BMI1, a component of the PRC1 complex that maintains mitochondrial balance, is a substrate of calpain.
The targeted nano-formulation reinstated BMI1 expression by obstructing its degradation through calpain, a protein that degrades other proteins in response to calcium levels.
This research has enhanced our understanding of the role of the hormone (E2) in managing oxidative stress among Parkinson’s patients. With ongoing studies into long-term safety and improved targeted delivery, this formulation could emerge as a safer medication to enhance the quality of life for those with Parkinson's,” the researchers remarked.
Previously, INST scientists demonstrated that a nano-formulation of melatonin—a hormone that the brain releases in darkness—could offer a therapeutic avenue for treating Parkinson's. This disease is among the most prevalent neurological disorders, resulting from the death of dopamine-producing neurons due to the aggregation of synuclein protein within the brain.
Current treatment options primarily alleviate symptoms without addressing the underlying condition, emphasizing the critical need for superior therapeutic interventions.
